The PCAC committee, which met on July 23–24, identified BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon as candidates for the FDA's list. While these recommendations are strictly advisory and subject to further rulemaking, they hold weight for Hydreight, which has spent years building the physician, pharmacy, and technology systems required to support peptide-based medicine. CEO Shane Madden stated that the company’s focus remains on compliant, physician-supervised delivery, noting that the committee's findings reinforce the validity of their previous investments rather than necessitating a change in direction.
Hydreight Maintains Strategy Following FDA Peptide Advisory Recommendations
Hydreight Technologies is reaffirming its long-term operational strategy after the FDA’s Pharmacy Compounding Advisory Committee recommended six peptide-related substances for potential inclusion on the 503A Bulks List. The company maintains that its existing infrastructure for physician-supervised care is already positioned to manage these therapeutic categories.
Since 2019, the company has scaled its VSDHOne platform to include over 12,000 licenses, a network of 300 physicians, and more than 3,000 nurses across the United States. This digital health ecosystem currently supports over 45 treatment offerings, including GLP-1 therapies, hormone optimization, and IV wellness. By maintaining established protocols and pharmacy relationships, Hydreight intends to continue evaluating additional treatment categories as regulatory pathways evolve, ensuring that all future expansions remain within legal and clinical requirements.
Comments (0)
No comments yet. Be the first!